Tarek Assi1, Elie El Rassy2, Samer Tabchi2, Toni Ibrahim2, Tania Moussa3, Ralph Chebib2, Fadi El Karak2, Fadi Farhat2, Georges Chahine2, Fadi Nasr2, Marwan Ghosn2, Joseph Kattan2. 1. Department of Oncology, Hotel Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon. tarekassi@gmail.com. 2. Department of Oncology, Hotel Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon. 3. Department of Radiology, Hotel Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.
Abstract
PURPOSE: The use of chemotherapy in the last month of life (CLML) of cancer patients is considered an aggressive approach to be avoided. We examined the practice of CLML in Lebanese cancer patients, and we investigated patient and tumor characteristics that justify this practice. To our knowledge, this is the first study describing CLML of Middle Eastern patients with advanced cancer. METHODS: We conducted this study at Hotel-Dieu de France University Hospital (HDF), Lebanon. Cases eligible for this study were all individuals diagnosed with cancer who died at HDF between the 1st of January and the 31st of December 2014. Demographic and clinical characteristics of the patients were obtained from the hospital registration records. Data concerning the management plan, primary malignancy and stage, chemo-sensitivity, line, type, and timing of chemotherapy in the last month of life were also obtained. RESULTS: Among the 130 cancer patients who were enrolled, CLML was administered to a total of 55 patients (42.3 %), of whom 26 patients (50 %) received more than one cytotoxic drug. Oral drug was only given to 9 patients (16.4 %). Interestingly, CLML increased the risk of death in the last month of life (p = 0.02), yet progression of disease constituted the major cause of death in this subgroup (54.6 %). The only variable to have statistical significant correlation with CLML was performance status (p = 0.03). The type of tumor and recent diagnosis of less than 2 months were also correlated to CLML (p = 0.03 and 0.024, respectively). CONCLUSION: The high percentage of patients receiving CLML underlines the difficulty of end-of-life discussions in patients from Middle Eastern societies. This is true in the context of a country with little availability of palliative care resources, where health policies should be more focused on incorporating palliative medicine in all medical strategies.
PURPOSE: The use of chemotherapy in the last month of life (CLML) of cancerpatients is considered an aggressive approach to be avoided. We examined the practice of CLML in Lebanese cancerpatients, and we investigated patient and tumor characteristics that justify this practice. To our knowledge, this is the first study describing CLML of Middle Eastern patients with advanced cancer. METHODS: We conducted this study at Hotel-Dieu de France University Hospital (HDF), Lebanon. Cases eligible for this study were all individuals diagnosed with cancer who died at HDF between the 1st of January and the 31st of December 2014. Demographic and clinical characteristics of the patients were obtained from the hospital registration records. Data concerning the management plan, primary malignancy and stage, chemo-sensitivity, line, type, and timing of chemotherapy in the last month of life were also obtained. RESULTS: Among the 130 cancerpatients who were enrolled, CLML was administered to a total of 55 patients (42.3 %), of whom 26 patients (50 %) received more than one cytotoxic drug. Oral drug was only given to 9patients (16.4 %). Interestingly, CLML increased the risk of death in the last month of life (p = 0.02), yet progression of disease constituted the major cause of death in this subgroup (54.6 %). The only variable to have statistical significant correlation with CLML was performance status (p = 0.03). The type of tumor and recent diagnosis of less than 2 months were also correlated to CLML (p = 0.03 and 0.024, respectively). CONCLUSION: The high percentage of patients receiving CLML underlines the difficulty of end-of-life discussions in patients from Middle Eastern societies. This is true in the context of a country with little availability of palliative care resources, where health policies should be more focused on incorporating palliative medicine in all medical strategies.
Entities:
Keywords:
CLML; Cancer; Chemotherapy; End of life; Middle Eastern; Palliative care
Authors: Amrallah A Mohammed; Abdullah S Al-Zahrani; Hafez M Ghanem; Mian U Farooq; Amr M El Saify; Hani M El-Khatib Journal: J Egypt Natl Canc Inst Date: 2015-02-25
Authors: Beate Mayrbäurl; Johannes M Giesinger; Sonja Burgstaller; Gudrun Piringer; Bernhard Holzner; Josef Thaler Journal: Support Care Cancer Date: 2015-07-01 Impact factor: 3.603
Authors: Jennifer W Mack; Anne Walling; Sydney Dy; Anna Liza M Antonio; John Adams; Nancy L Keating; Diana Tisnado Journal: Cancer Date: 2015-02-11 Impact factor: 6.860
Authors: Jane C Weeks; Paul J Catalano; Angel Cronin; Matthew D Finkelman; Jennifer W Mack; Nancy L Keating; Deborah Schrag Journal: N Engl J Med Date: 2012-10-25 Impact factor: 91.245
Authors: Ziad Bakouny; Tarek Assi; Elie El Rassy; Karen Daccache; Clarisse Kattan; Aline Tohme; Marie Claire Mouhawej; Joseph Kattan Journal: Support Care Cancer Date: 2018-11-07 Impact factor: 3.603
Authors: Tarek Assi; Elie El Rassy; Tony Ibrahim; Tania Moussa; Aline Tohme; Fadi El Karak; Fadi Farhat; Salma Faddoul; Marwan Ghosn; Joseph Kattan Journal: Support Care Cancer Date: 2016-10-13 Impact factor: 3.603
Authors: Fadi Farhat; Abdulaziz Al Farsi; Ahmed Mohieldin; Bassim Al Bahrani; Eman Sbaity; Hassan Jaffar; Joseph Kattan; Kakil Rasul; Khairallah Saad; Tarek Assi; Waleed El Morsi; Rafid A Abood Journal: World J Clin Cases Date: 2020-02-06 Impact factor: 1.337
Authors: Andrea A Martoni; Barbara Melotti; Claudia Degli Esposti; Vita Mutri; Giorgio Lelli; Silvia Ansaloni; Erico Piva; Elena Strocchi; Franco Pannuti Journal: ESMO Open Date: 2017-03-14